Press coverage about C R Bard (NYSE:BCR) has been trending positive recently, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. C R Bard earned a media sentiment score of 0.32 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 45.39397573175 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
C R Bard has a 12 month low of $223.02 and a 12 month high of $337.73. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $24,140.00, a PE ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52.
C R Bard (NYSE:BCR) last issued its earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.96 by $0.06. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. The firm had revenue of $989.80 million for the quarter, compared to analysts’ expectations of $990.64 million. During the same period in the previous year, the firm posted $2.64 earnings per share. The business’s revenue was up 5.1% compared to the same quarter last year. equities analysts predict that C R Bard will post 11.89 EPS for the current fiscal year.
A number of analysts have commented on the company. Zacks Investment Research upgraded C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price target on the stock in a research note on Tuesday, December 26th. ValuEngine downgraded C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Barclays lifted their target price on C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research report on Monday, November 6th. Cowen reiterated a “hold” rating and set a $317.00 target price on shares of C R Bard in a research report on Friday, November 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of C R Bard in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $311.43.
In related news, insider Christopher S. Holland sold 38,242 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $334.04, for a total value of $12,774,357.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David M. Barrett sold 3,344 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $327.31, for a total value of $1,094,524.64. The disclosure for this sale can be found here. Insiders have sold 129,681 shares of company stock worth $43,125,017 over the last three months. 0.80% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/01/14/positive-media-coverage-somewhat-unlikely-to-affect-c-r-bard-bcr-share-price-updated-updated.html.
C R Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.